The value of osteoporosis interventions: evaluating the cost-effectiveness and incorporating patients’ preference

点击翻译按钮获取中文摘要

Osteoporosis (OP) poses substantial disease and economic burden. Many medications are publicly available and subsidized in Australia, and many new medications are on the horizon. Their value for money, however, is questionable without solid health economic evidence. In addition, patient preference for OP treatment is not well understood. My project is to develop a global health economics model to identify cost-effective treatments, and to elicit patient preference for different OP treatments.